ONX 0801

Drug Profile

ONX 0801

Alternative Names: BGC 945; BTG-945

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BTG; The Institute of Cancer Research
  • Developer Onyx Pharmaceuticals; Royal Marsden NHS Foundation Trust; The Institute of Cancer Research
  • Class Antineoplastics; Quinazolines
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (IV, Infusion)
  • 06 Jun 2017 Efficacy and safety data from a phase I trial in Solid tumours released by The Institute of Cancer Research
  • 02 Jun 2017 Pharmacokinetics and efficacy data from a phase-I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top